ROTHBLATT MARTINE A sold $4.8M of UTHR (indirect holdings)

The FDA approved United Therapeutics' Phase 1 trial for treprostinil-iloprost SMI, a pulmonary arterial hypertension treatment. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.

United Therapeutics (UTHR) received FDA clearance for a phase 1 trial of treprostinil-iloprost SMI, a treatment for pulmonary arterial hypertension. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled therapy for pulmonary arterial hypertension (PAH). The Phase 1 trial will assess safety and pharmacokinetics in healthy volunteers. If successful, a Phase 2 trial in PAH patients is planned for 2027. UTHR stock closed at $591.20, down 0.28%.

United Therapeutics (UTHR) received FDA clearance for a Phase 1 trial of Treprostinil-Iloprost SMI, an inhaled therapy for pulmonary arterial hypertension. The study will assess safety and pharmacokinetics in healthy volunteers. The company plans a Phase 2 trial in 2027 if initial results are successful. PAH affects 500,000 people worldwide.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.